Cantargia AB (publ) (FRA:7V3)

Market Cap	104.07M +168.1%
Revenue (ttm)	29.26M
Net Income	13.58M
EPS	0.05
Shares Out	n/a
PE Ratio	7.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	516
Open	0.4430
Previous Close	0.4450
Day's Range	0.4430 - 0.4575
52-Week Range	0.0635 - 0.5610
Beta	n/a
RSI	49.76
Earnings Date	Feb 20, 2026

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 23
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7V3

Financial Performance

Financial numbers in SEK